Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population.
about
Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical applicationNuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysisConcentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patientsNon-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.Translational regulation of RPA2 via internal ribosomal entry site and by eIF3aMultidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: A meta-analysisDoxorubicin pathways: pharmacodynamics and adverse effects.Genetic variation of the ABC transporter gene ABCC1 (Multidrug resistance protein 1-MRP1) in the Polish populationAssociation of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response.eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies.Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia.ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents.Cancer cell resistance mechanisms: a mini review.Importance of ABCC1 for cancer therapy and prognosis.Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Association of Two Polymorphic Codons in P53 and ABCC1 Promoter with Prostate CancerABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population.Association ofHMGB1andHMGB2genetic polymorphisms with lung cancer chemotherapy responseThe ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients
P2860
Q28468693-57DE3369-4B71-4479-9A07-EC76083DDB20Q28535696-3EF86843-50D2-4173-8132-8E1327BA104DQ33776536-E631BD15-6BEE-4BE1-93B9-10ED70C7AFF1Q33894826-B5224F68-D839-41CC-B732-C91389E0A9A6Q33982601-349011AB-09B0-4FBC-A1BB-036AA8855BB7Q34130459-B11590FE-9807-4FD7-87C2-2928D12D073DQ34325669-6C40DB1C-4610-45E2-A822-A3EDF9356708Q34450660-6D7489E4-EAED-4351-822A-C81D3B6A4382Q34580793-DFC111E7-5291-4BF3-9290-BA6E3DCCCA46Q34607510-FD208266-F713-44ED-A47E-196B76005B68Q35048393-B0606293-2B9C-48C3-B907-D42306D75BB3Q35784144-8F06FDE0-E81B-41A5-B2F2-4A7E5A0EA15DQ35884735-30B18D37-8301-4388-A70A-B3F66DD7920CQ36413207-29009764-7D7D-4391-9C20-E4A5731FCF49Q36891521-5A7F80C5-7616-43DF-A5EC-C617DD1F4E3EQ37611366-1FCE8C47-5B0F-4503-83F7-28BF7567FFDDQ37719572-26E17AE4-A9A1-471A-A3B9-CCC5430C4D75Q37830057-C616E438-1AD8-46AE-9C6D-B4C670E4B859Q38197531-3ADE25DE-4172-4548-B1B4-3CB85CA9ECDBQ38199535-0101ED54-CCE9-4B5E-83FD-F08508CCF8D4Q38613161-4CAC4CF5-D683-4A2B-954E-377FBAB16865Q38909984-7BAECC8A-9F29-4F05-BBB4-A46CEB592CD0Q38933314-B0AC5254-4E53-495D-B1FD-D81B519BAB57Q41674458-67945550-EA92-48B8-AFD3-0CB9D9739A21Q54360840-4390FDE0-E0EC-446B-9010-AE8C2F0A7EE5Q57500224-C3DF4C2E-B964-4125-A1B9-A64A9AADFE5CQ57500237-E8927A95-33F1-43AF-BD9B-21BBA5AA6DFE
P2860
Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization and analyses ...... rphisms in Chinese population.
@en
Characterization and analyses of multidrug resistance-associated protein 1
@nl
type
label
Characterization and analyses ...... rphisms in Chinese population.
@en
Characterization and analyses of multidrug resistance-associated protein 1
@nl
prefLabel
Characterization and analyses ...... rphisms in Chinese population.
@en
Characterization and analyses of multidrug resistance-associated protein 1
@nl
P2093
P2860
P1476
Characterization and analyses ...... rphisms in Chinese population.
@en
P2093
Hong-Hao Zhou
Jian-Ting Zhang
Mei-Zuo Zhong
Qiong Huang
Youyun Yang
P2860
P304
P356
10.1097/FPC.0B013E328323F680
P577
2009-03-01T00:00:00Z